Octreotide Medicine 04 June 2026 Extended indication Octreotide monotherapy for first line treatment of unresectable and/or metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumour disease in adults and elderly. Therapeutic value No estimate possible yet Total cost € 11,088,000.00 Registration phase Clinical trials Product Active substance Octreotide Domain Oncology Reason of inclusion Indication extension IND Main indication Neuroendocrine cancer Extended indication Octreotide monotherapy for first line treatment of unresectable and/or metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumour disease in adults and elderly. Current proprietary name Already available biosimilars / generics Proprietary name Mycapssa Manufacturer Camurus Portfolio holder Mechanism of action Route of administration Subcutaneous Therapeutical formulation Injection Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Somatostatineanaloog. Langwerkende octreotide subcutaan depot. Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity ATMP No Submission date September 2026 Expected Registration October 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Tijdslijn op basis van IHSI-inschatting. Therapeutic value Current treatment options Lanreotide Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Er zijn nog geen resultaten bekend. Duration of treatment Frequency of administration 1 times every 2 weeks Dosage per administration 20mg References NCT05050942 (SORENTO) Additional remarks Expected patient volume per year Patient volume < 630 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NKR 2022 (1); Das & Dasari. Curr Oncol Rep. 2021 (2). Additional remarks Jaarlijks worden in Nederland ruim 900 diagnoses neuro-endocrine tumor (NET) gesteld (1). 55 tot 70% van NETs zijn gastro-enteropancreatische NETs (GEP-NETs) (2). Expected cost per patient per year Cost € < 17,600.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Medicijnkosten.nl Additional remarks Octreotide depot Teva 20mg: €734,91 (inclusief BTW). Een jaarbehandeling kost dan €17.530 per patiënt per jaar (exclusief BTW) (€734,91/1,09∗26). Potential total cost per year Total cost € 11,088,000.00 Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks